Redeye: SynAct Pharma - Adding an indication

Mon, Oct 28, 2019 07:52 CET

We had the opportunity to dig deeper in to the commercial potential for AP1189 in nephrotic syndrome. As a result, we raise our base case valuation to SEK 17 per share.

Read more and download the research update: http://bit.ly/2WilqLy

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/